title: Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Frigeri
authors.forename: Manuela
authors.initials: M
authors.lastname: Arcamone
authors.forename: Luigia
authors.initials: L
authors.lastname: Luciano
authors.forename: Raffaele
authors.initials: R
authors.lastname: Di Francia
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.forename: Antonio
authors.initials: A
authors.lastname: Pinto
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D000069439:Dasatinib; D016313:Genes, abl / Q000502:physiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib